Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other research analysts have also recently commented on KERX. ValuEngine raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Maxim Group set a $9.00 price target on Keryx Biopharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 27th. Cowen and Company reaffirmed a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th. Morgan Stanley reissued an “equal weight” rating and set a $7.00 price objective (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. Finally, Zacks Investment Research raised Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a report on Wednesday, July 12th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $7.48.

Keryx Biopharmaceuticals (KERX) traded up 1.47% on Wednesday, reaching $6.90. The company’s stock had a trading volume of 792,064 shares. Keryx Biopharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.38. The firm’s market cap is $819.38 million. The firm has a 50 day moving average of $7.24 and a 200 day moving average of $6.20.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.60. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The firm had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.51 million. During the same period in the prior year, the company earned ($0.42) EPS. The firm’s quarterly revenue was up 62.4% on a year-over-year basis. Analysts anticipate that Keryx Biopharmaceuticals will post ($1.23) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Keryx Biopharmaceuticals, Inc. (KERX) Upgraded at BidaskClub” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/16/keryx-biopharmaceuticals-inc-kerx-upgraded-at-bidaskclub.html.

Hedge funds have recently modified their holdings of the company. Stifel Financial Corp boosted its stake in shares of Keryx Biopharmaceuticals by 11.5% in the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 3,478 shares during the period. Rice Hall James & Associates LLC boosted its stake in shares of Keryx Biopharmaceuticals by 3.0% in the first quarter. Rice Hall James & Associates LLC now owns 1,340,649 shares of the biopharmaceutical company’s stock worth $8,258,000 after buying an additional 39,656 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Keryx Biopharmaceuticals by 29.1% in the first quarter. Janney Montgomery Scott LLC now owns 66,565 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 15,000 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of Keryx Biopharmaceuticals by 60.1% in the first quarter. Parametric Portfolio Associates LLC now owns 192,982 shares of the biopharmaceutical company’s stock worth $1,189,000 after buying an additional 72,436 shares during the period. Finally, Bank of Montreal Can bought a new stake in shares of Keryx Biopharmaceuticals during the first quarter worth about $434,000. 57.76% of the stock is currently owned by institutional investors and hedge funds.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.